HRs (and 95% CIs) of functional limitations for mortality stratified by tumour stage and body mass index*
| Other-cause mortality (number of deaths=436) | Breast cancer mortality (number of deaths=317) | |||
|---|---|---|---|---|
| Baseline | Decline | Baseline | Decline | |
| Stage of breast cancer at diagnosis* | ||||
| Local, N=523 | Number of deaths=274 | Number of deaths=93 | ||
| Functional limitations (continuous) | 1.11 (1.03 to 1.19) | 1.07 (0.94 to 1.23) | 1.04 (0.92 to 1.17) | 1.16 (0.97 to 1.38) |
| Functional limitations (≥1 vs 0) | 1.46 (1.05 to 2.03) | 1.06 (0.75 to 1.49) | 1.30 (0.76 to 2.23) | 1.02 (0.59 to 1.77) |
| Regional and remote, N=452 | Number of deaths=162 | Number of deaths=224 | ||
| Functional limitations (continuous) | 1.03 (0.94 to 1.14) | 1.19 (1.00 to 1.43) | 1.02 (0.94 to 1.10) | 1.08 (0.92 to 1.26) |
| Functional limitations (≥1 vs 0) | 1.58 (0.90 to 2.75) | 1.61 (1.03 to 2.52) | 0.66 (0.47 to 0.93) | 1.19 (0.82 to 1.73) |
| Body mass index at baseline, (kg/m2)† | ||||
| <25, N=454 | Number of deaths=210 | Number of deaths=128 | ||
| Functional limitations (continuous) | 1.11 (1.01 to 1.22) | 1.12 (0.94 to 1.32) | 1.01 (0.90 to 1.14) | 1.13 (0.94 to 1.36) |
| Functional limitations (≥1 vs 0) | 1.80 (1.14 to 2.84) | 1.45 (0.93 to 2.27) | 0.74 (0.46 to 1.18) | 1.00 (0.57 to 1.73) |
| 25–30, N=323 | Number of deaths=148 | Number of deaths=109 | ||
| Functional limitations (continuous) | 1.07 (1.02 to 1.13) | 1.10 (1.00 to 1.21) | 0.99 (0.93 to 1.06) | 1.17 (1.05 to 1.31) |
| Functional limitations (≥1 vs 0) | 1.48 (1.13 to 1.94) | 1.24 (0.95 to 1.60) | 0.71 (0.54 to 0.95) | 1.28 (0.94 to 1.73) |
| >30, N=198 | Number of deaths=78 | Number of deaths=80 | ||
| Functional limitations (continuous) | 0.78 (0.60 to 1.02) | 1.09 (0.68 to 1.76) | 1.08 (0.92 to 1.27) | 1.48 (1.09 to 2.02) |
| Functional limitations (≥1 vs 0) | 0.62 (0.18 to 2.12) | 2.15 (0.70 to 6.60) | 1.50 (0.61 to 3.66) | 3.05 (1.32 to 7.03) |
*Models were stratified by age at breast cancer diagnosis and additionally adjusted for race, comorbidity, breast cancer treatment, body mass index, financial adequacy, education, smoking, positive lymph node involvement, tumour size at diagnosis and period of study entry.
†Models were stratified by age at breast cancer diagnosis and additionally adjusted for race, comorbidity, breast cancer stage, treatment, financial adequacy, education, smoking, positive lymph node involvement, tumour size at diagnosis and period of study entry.